|
|
Celecoxib pathways: pharmacokinetics and pharmacodynamics. Pharmacogenetics and genomics. 2012. Gong Li, et al. [Article:22336956@PubMed] |
|
|
Genetic and genomic predictors of anti-TNF response. Pharmacogenomics. 2011. Prajapati Rita, et al. [Article:22044414@PubMed] |
|
|
Interaction networks of lithium and valproate molecular targets reveal a striking enrichment of apoptosis functional clusters and neurotrophin signaling. The pharmacogenomics journal. 2011. Gupta A, et al. [Article:21383773@PubMed] |
|
|
Role of cyclooxygenase-2 and 5-lipoxygenase polymorphisms in Alzheimer's disease in a population from northern Italy: implication for pharmacogenomics. Journal of Alzheimer's disease : JAD. 2010. Listì Florinda, et al. [Article:20110601@PubMed] |
|
|
PharmGKB summary: very important pharmacogene information for PTGS2. Pharmacogenetics and genomics. 2010. Thorn Caroline F, et al. [Article:21063235@PubMed] |
|
|
Genetic polymorphisms and the cardiovascular risk of non-steroidal anti-inflammatory drugs. The American journal of cardiology. 2010. St Germaine Christine G, et al. [Article:20538124@PubMed] |
|
|
Growth factor regulation of prostaglandin-endoperoxide synthase 2 (Ptgs2) expression in colonic mesenchymal stem cells. The Journal of biological chemistry. 2010. Walker Monica R, et al. [Article:20018844@PubMed] |
|
|
A large-scale candidate gene approach identifies SNPs in SOD2 and IL13 as predictive markers of response to preoperative chemoradiation in rectal cancer. The pharmacogenomics journal. 2010. Ho-Pun-Cheung A, et al. [Article:20644561@PubMed] |
|
|
Polymorphic human prostaglandin H synthase-2 proteins and their interactions with cyclooxygenase substrates and inhibitors. The pharmacogenomics journal. 2010. Liu W, et al. [Article:20548327@PubMed] |
|
|
Variation in eicosanoid genes, non-fatal myocardial infarction and ischemic stroke. Atherosclerosis. 2009. Lemaitre Rozenn N, et al. [Article:19046748@PubMed] |
|
|
Prostaglandin synthase 2/cyclooxygenase 2 (PTGS2/COX2) 8473T>C polymorphism associated with prognosis for patients with colorectal cancer treated with capecitabine and oxaliplatin. Cancer chemotherapy and pharmacology. 2009. Kim Jong Gwang, et al. [Article:19219602@PubMed] |
|
|
Role of inflammation gene polymorphisms on pain severity in lung cancer patients. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2009. Reyes-Gibby Cielito C, et al. [Article:19773451@PubMed] |
|
|
The genetics of antiplatelet drug resistance. Clinical genetics. 2009. Feher G, et al. [Article:19067731@PubMed] |
|
|
Interaction of cyclooxygenase-2 variants and smoking in pancreatic cancer: a possible role of nucleophosmin. Gastroenterology. 2009. Zhao Dan, et al. [Article:19422084@PubMed] |
|
|
Variability in the response to cyclooxygenase inhibitors: toward the individualization of nonsteroidal anti-inflammatory drug therapy. Journal of investigative medicine : the official publication of the American Federation for Clinical Research. 2009. Grosser Tilo. [Article:19602986@PubMed] |
|
|
Pharmacogenetics in cardiovascular antithrombotic therapy. Journal of the American College of Cardiology. 2009. Marín Francisco, et al. [Article:19744613@PubMed] |
|
|
Genes that mediate breast cancer metastasis to the brain. Nature. 2009. Bos Paula D, et al. [Article:19421193@PubMed] |
|
|
Evolving novel anti-HER2 strategies. The lancet oncology. 2009. Jones Kellie L, et al. [Article:19959074@PubMed] |
|
|
Genome-wide association scan identifies a prostaglandin-endoperoxide synthase 2 variant involved in risk of knee osteoarthritis. American journal of human genetics. 2008. Valdes Ana M, et al. [Article:18471798@PubMed] |
|
|
Increased risk of incident stroke associated with the cyclooxygenase 2 (COX-2) G-765C polymorphism in African-Americans: the Atherosclerosis Risk in Communities Study. Atherosclerosis. 2008. Kohsaka Shun, et al. [Article:17350020@PubMed] |
|
|
Acceleration of cardiovascular disease by a dysfunctional prostacyclin receptor mutation: potential implications for cyclooxygenase-2 inhibition. Circulation research. 2008. Arehart Eric, et al. [Article:18323528@PubMed] |
|
|
Cyclooxygenase polymorphisms and risk of cardiovascular events: the Atherosclerosis Risk in Communities (ARIC) study. Clinical pharmacology and therapeutics. 2008. Lee C R, et al. [Article:17495879@PubMed] |
|
|
Clinical use and pharmacological properties of selective COX-2 inhibitors. European journal of clinical pharmacology. 2008. Shi Shaojun, et al. [Article:17999057@PubMed] |
|
|
Variable platelet response to aspirin and clopidogrel in atherothrombotic disease. Circulation. 2007. Maree Andrew O, et al. [Article:17452618@PubMed] |
|
|
The pharmacogenetics of antiplatelet drugs. Current opinion in investigational drugs (London, England : 2000). 2007. Marín Francisco, et al. [Article:17408116@PubMed] |
|
|
Pharmacogenetics of EGFR and VEGF inhibition. Drug discovery today. 2007. Pander Jan, et al. [Article:18061885@PubMed] |
|
|
STAT3 polymorphism predicts interferon-alfa response in patients with metastatic renal cell carcinoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2007. Ito Noriyuki, et al. [Article:17602083@PubMed] |
|
|
Pyrosequencing of polymorphisms in the COX-2 gene (PTGS2) with reported clinical relevance. Pharmacogenomics. 2007. Skarke Carsten, et al. [Article:18085997@PubMed] |
|
|
COX-2 suppresses tissue factor expression via endocannabinoid-directed PPARdelta activation. The Journal of experimental medicine. 2007. Ghosh Mallika, et al. [Article:17724132@PubMed] |
|
|
Aspirin and the risk of colorectal cancer in relation to the expression of COX-2. The New England journal of medicine. 2007. Chan Andrew T, et al. [Article:17522398@PubMed] |
|
|
Genetically mediated interindividual variation in analgesic responses to cyclooxygenase inhibitory drugs. Clinical pharmacology and therapeutics. 2006. Lee Yun-Sil, et al. [Article:16678543@PubMed] |
|
|
The cyclooxygenase 2 genetic variant -765G>C does not modulate the effects of celecoxib on prostaglandin E2 production. Clinical pharmacology and therapeutics. 2006. Skarke Carsten, et al. [Article:17178263@PubMed] |
|
|
Marked interindividual variability in the response to selective inhibitors of cyclooxygenase-2. Gastroenterology. 2006. Fries Susanne, et al. [Article:16401468@PubMed] |
|
|
Cyclin D1 and epidermal growth factor polymorphisms associated with survival in patients with advanced colorectal cancer treated with Cetuximab. Pharmacogenetics and genomics. 2006. Zhang Wu, et al. [Article:16788380@PubMed] |
|
|
Hippocampal upregulation of the cyclooxygenase-2 gene following neonatal clomipramine treatment (a model of depression). The pharmacogenomics journal. 2006. Cassano P, et al. [Article:16568149@PubMed] |
|
|
PTGS2 (COX-2) -765G > C promoter variant reduces risk of colorectal adenoma among nonusers of nonsteroidal anti-inflammatory drugs. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2005. Ulrich Cornelia M, et al. [Article:15767339@PubMed] |
|
|
Colorectal adenoma risk is modified by the interplay between polymorphisms in arachidonic acid pathway genes and fish consumption. Carcinogenesis. 2005. Siezen Christine L E, et al. [Article:15550453@PubMed] |
|
|
Identification of functional genetic variants in cyclooxygenase-2 and their association with risk of esophageal cancer. Gastroenterology. 2005. Zhang Xuemei, et al. [Article:16083713@PubMed] |
|
|
Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. The New England journal of medicine. 2005. Bresalier Robert S, et al. [Article:15713943@PubMed] |
|
|
Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. The New England journal of medicine. 2005. Solomon Scott D, et al. [Article:15713944@PubMed] |
|
|
Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. The New England journal of medicine. 2005. Nussmeier Nancy A, et al. [Article:15713945@PubMed] |
|
|
Signal transduction pathways regulating cyclooxygenase-2 expression: potential molecular targets for chemoprevention. Biochemical pharmacology. 2004. Chun Kyung-Soo, et al. [Article:15313405@PubMed] |
|
|
Interaction between cyclooxygenase-2 gene polymorphism and dietary n-6 polyunsaturated fatty acids on colon cancer risk: the Singapore Chinese Health Study. British journal of cancer. 2004. Koh W-P, et al. [Article:15150618@PubMed] |
|
|
Overexpression of the embryonic-lethal abnormal vision-like protein HuR in ovarian carcinoma is a prognostic factor and is associated with increased cyclooxygenase 2 expression. Cancer research. 2004. Denkert Carsten, et al. [Article:14729623@PubMed] |
|
|
HMG-CoA reductase inhibitors induce COX-2 gene expression in murine macrophages: role of MAPK cascades and promoter elements for CREB and C/EBPbeta. Experimental cell research. 2004. Chen Jui-Ching, et al. [Article:15530865@PubMed] |
|
|
Relationship between COX-2 specific inhibitors and hypertension. Hypertension. 2004. Solomon Daniel H, et al. [Article:15226279@PubMed] |
|
|
A polymorphism in the cyclooxygenase 2 gene as an inherited protective factor against myocardial infarction and stroke. JAMA : the journal of the American Medical Association. 2004. Cipollone Francesco, et al. [Article:15138244@PubMed] |
|
|
COX-2 inhibition and cancer: experimental findings and clinical correlates. The West Virginia medical journal. 2004. Roberts Elizabeth Gail, et al. [Article:15384741@PubMed] |
|
|
The RNA-binding protein HuR regulates the expression of cyclooxygenase-2. The Journal of biological chemistry. 2003. Sengupta Sibani, et al. [Article:12704185@PubMed] |
|
|
COX-2-selective inhibitors in the treatment of arthritis. Cleveland Clinic journal of medicine. 2002. Schnitzer Thomas J, et al. [Article:12086290@PubMed] |
|
|
Dexamethasone destabilizes cyclooxygenase 2 mRNA by inhibiting mitogen-activated protein kinase p38. Molecular and cellular biology. 2001. Lasa M, et al. [Article:11154265@PubMed] |
|
|
Celecoxib, a COX-2--specific inhibitor: the clinical data. American journal of orthopedics (Belle Mead, N.J.). 1999. Fort J. [Article:10193998@PubMed] |
|
|
Repression of cyclooxygenase-2 and prostaglandin E2 release by dexamethasone occurs by transcriptional and post-transcriptional mechanisms involving loss of polyadenylated mRNA. The Journal of biological chemistry. 1998. Newton R, et al. [Article:9822711@PubMed] |
|
|
Prostaglandin endoperoxide H synthases (cyclooxygenases)-1 and -2. The Journal of biological chemistry. 1996. Smith W L, et al. [Article:8969167@PubMed] |